Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab. Novartis paid $1.4B for drug via Tourmaline Bio.
ESC Congress in Munich (Credit: ESC on Facebook)
August 29, 2026 02:55 AM EDT
Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure
Elizabeth Cairns
Senior biopharma journalist
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3…
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different…
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between…
Novo Nordisk (NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed…
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse…
In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an…
